Peter Rothschild, President of BioGaia, summarises 2015 and answers questions regarding;

  • reasons behind a weaker trend during the fourth quarter
  • any possible factors that may affect sales during the upcoming year
  • what needs to be accomplished in order to reach doubel-digit growth also the next year
  • the proposed listing of subsidary IBT and the progress they are making in developing a new drug against NEC
  • expectations, oportunities and challenges for the upcoming year